Mutations in some MDS-associated genes predict the therapeutic efficacy of HMA (e.g., TET2, DNMT3A, IDH1, IDH2, ASXL1, CBL, RAS, and SF3B1 [23]). This evidence concerns the gene CBL and myelodysplastic syndrome.